Company Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases.
Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases.
The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy.
The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.
Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Country | United States |
| Founded | 2004 |
| IPO Date | May 2, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Todd Brady |
Contact Details
Address: 131 Hartwell Avenue, Suite 320 Lexington, Massachusetts 02421 United States | |
| Phone | 781 761 4904 |
| Website | aldeyra.com |
Stock Details
| Ticker Symbol | ALDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001341235 |
| CUSIP Number | 01438T106 |
| ISIN Number | US01438T1060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Todd C. Brady M.D., Ph.D. | Chief Executive Officer, President and Director |
| Dr. Stephen G. Machatha Ph.D. | Chief Development Officer |
| Michael Alfieri | Principal Financial and Accounting Officer |
| David Burke | Head of Investor Relations |
| Laura Nichols | Operations Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Oct 3, 2024 | 8-K | Current Report |
| Oct 2, 2024 | 8-K | Current Report |
| Sep 3, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 144 | Filing |
| Aug 12, 2024 | 144 | Filing |
| Aug 8, 2024 | 8-K | Current Report |
| Aug 1, 2024 | 424B5 | Filing |